Chemotherapy for Prostate Cancer: a Shared Decision

This program is sponsored by Sanofi. Participants have been compensated and/or received an honorarium from Sanofi in connection with this podcast. This content was jointly developed by the participants and Sanofi. This is a promotional event and no CME credits are offered.

Healthcare providers face a communication challenge when it comes to talking about chemotherapy with their patients who have prostate cancer. This podcast, geared toward oncologists, primary physicians, and nurse practitioners, explores some of the myths and misconceptions men and their caregivers may have about chemotherapy as a treatment option for prostate cancer. Our experts provide tips for how to talk with patients about their fears, and they offer information to encourage shared decision making so that patients understand whether chemotherapy may be the right choice for prostate cancer.

Host
Pedro Barata, MD, MSc, associate professor and medical oncologist, Tulane Comprehensive Cancer Center

Guests
Rana McKay, MD, associate professor and medical oncologist, UC San Diego Health

Vivek Narayan, MD, MS, assistant professor of medicine, University of Pennsylvania; medical oncologist Hospital of University of Pennsylvania

View Details

Presenters have been compensated by Sanofi in connection with this presentation.

Are you a physician, oncologist, or nurse practitioner who cares for men who have advanced prostate cancer? If so, you may face challenges talking with your patients about considering chemotherapy. Sometimes a lack of information is all it takes for patients to feel worried or pessimistic about this treatment option. This podcast, Chemotherapy for Prostate Cancer, a Shared Decision, explores misconceptions patients and caregivers have about chemotherapy and ways healthcare providers may help patients understand when chemotherapy may be the right choice for them.

View Details

This episode focuses on patients’ fears and misconceptions about chemotherapy and features a discussion between Dr Barata and Dr McKay about how they talk with patients contemplating chemotherapy as a treatment option for advanced prostate cancer.

You will learn the following:

How chemotherapy has advanced over the past century and impacted the risk benefit profile
Treatments options available for advanced metastatic castration-resistant prostate cancer (mCRPC)
Common misconceptions patients and caregivers have about chemotherapy and ways healthcare providers may help patients understand when chemotherapy might be the right choice for them
How to talk with patients about their concerns
What strategies and resources can support shared decision making about chemotherapy as an option for mCRPC

HostDr Pedro Barata is associate professor at Tulane Medical School and is a genitourinary medical oncologist at Tulane Comprehensive Cancer Center. His areas of specialty include prostate, kidney, and bladder cancers. Dr Barata has authored and coauthored scores of research publications and textbook chapters and is a reviewer and editor for several peer-reviewed oncology publications, including The Oncologist, Clinical Genitourinary Cancer journal, and Translational Oncology journal. He has presented at numerous national and international meetings.

GuestDr Rana McKay is associate professor at UC San Diego, Health School of Medicine and is a board-certified medical oncologist. She specializes in treating urogenital cancers and leads a multidisciplinary prostate cancer clinic for men who have aggressive prostate cancer. She has been a principal investigator for several clinical trials and has published numerous articles in leading peer-reviewed journals, such as Nature, Lancet, Journal of Clinical Oncology, and others. Her research focus includes novel biomarkers and therapeutic outcomes for patients who have genitourinary cancer.

View Details

This episode, which addresses oncologists, primary physicians, and nurse practitioners, takes a dive into why and when chemotherapy is an option for some patients who have metastatic castration-resistant prostate cancer (mCRPC). Dr Pedro Barata and guest Dr Vivek Narayan review therapeutic agents and explore therapies considering potential side effects and which patients may benefit from chemotherapy.

You will learn the following:

Newer treatment approaches, such as testing for biomarkers for targeted therapies like radiopharmaceuticals, PARP inhibitors, and IO therapies, as well as hormonal therapies
The importance of genetic testing and molecular profiling
Patients with specific genetic mutations through profiling may have additional treatments available to them
Determining sequential therapies
Balancing potential clinical benefit and safety profile
When and why taxane chemotherapy may offer a treatment
Introducing chemotherapy to appropriate patients who have advanced prostate cancer

HostDr Pedro Barata is associate professor at Tulane Medical School and is a genitourinary medical oncologist at Tulane Comprehensive Cancer Center and his areas of specialty include prostate, kidney, and bladder cancers. Dr Barata has authored and coauthored scores of research publications and textbook chapters and is a reviewer and editor for several peer-reviewed oncology journals, including The Oncologist, Clinical Genitourinary Cancer journal, and Translational Oncology journal. He has presented at numerous national and international meetings.

GuestDr Vivek Narayan is assistant professor of medicine at the University of Pennsylvania and a medical oncologist at Penn Genitourinary and Urologic Cancer Program and the Penn Neuroendocrine Tumor Program. Dr Narayan sees patients across the prostate cancer disease spectrum and he participates in clinical trials with novel therapies to treat the disease. His research and extensive publications focus on prostate cancer, renal cell carcinoma, kidney cancer, and bladder cancer.

Chemotherapy for Prostate Cancer: a Shared Decision: Recent Episodes

Artcraft Health